Randomized Trialhigh evidence
Mirtazapine for Methamphetamine Use Disorder: A Randomized Clinical Trial.
JAMA psychiatry·June 1, 2026·PMID 41920558
Why it mattersThere are currently no approved pharmacotherapies for methamphetamine use disorder, a major global health problem. This trial provides evidence that mirtazapine, an accessible antidepressant, may modestly reduce methamphetamine use in routine clinical settings, offering a potential treatment option where none exists.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled